SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

News > Research

Read more breaking news

 

 

EU-backed beta glucan trial explores immunity benefits

By Shane Starling , 26-Oct-2012
Last updated on 29-Oct-2012 at 09:49 GMT2012-10-29T09:49:39Z

EU-backed beta glucan trial explores immunity benefits

An EU-backed, 240-person trial is underway to investigate the ability of a range of beta-glucans to boost immune systems, with European Union health claim learnings firmly in mind.

The data will be analysed using, many biomarkers including those indicative for the innate immune system, the adaptive immune system, the effect on gut microbiota and metabolites generated by the gut microbiota as a response to the intervention.” 

The trial involes Wellmune yeast beta-glucan, OatWell oat beta-glucan, NAXUS wheat arabinoxylan, beta-glucan of Shiitake mushroom and a powder containing exopolysaccharides produced by Lactobacillus mucosae.

The trial is part of the FibeBiotics project that began in January, unites business and academia, has €6m in EU funding, and is set to complete in 2016. Non-digestible polysaccharides (NPS) are its core focus.

The project involves four European universities, five research institutes, and eight companies.

One of the partners, Clinical Research Centre (CRC) organised the current trial. CEO Christiane Laue said: “This pilot study should learn us what NPS compounds are interested to include in follow-up studies, directly learn what number of persons should be included in a pivotal trial to reach significant effects and what biomarkers are most interested to include in such a large study”. 

FibeBiotics won funding over about 30 other project proposals because, in part, it has determined to mould its research around requirements under the EU nutrition and health claims regulation (NHCR) as published by the European Food Safety Authority (EFSA).

Project goals

Project chief, Jurriaan Mes, from the Food & Bio-based Research department of Wageningen University in the Netherlands said the project was taking shape after a “very intense” beginning.

“NPS compounds needed to be isolated, needed to be packed according to the double blind placebo controlled design, the ethical protocol had to be written, pilots for biomarkers analysis performed etc. But thanks to the collaborative action of the dedicated partners we managed everything in time,” Mes said.

The project seeks to, “standardise analytical methods, set up in vitro assays to support product development, study the mechanism of action, validate biomarkers and conduct clinical trials on non-digestible polysaccharides.”
This is the first large EU project where researchers work together with the industry and aim to develop end-products that might be able to pass EFSA claim evaluation and do this by using the EFSA guidelines in the area of gut and immune function. FibeBiotics beat out 30 other projects on bioactive compounds and functional products that were petitioned to the EU.

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars